15 June 2021
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company engaged in the discovery and development of oral therapeutics for severe viral infections, today announced the appointment of Claudio Avila, MB, BS, Ph.D., as Senior Vice President of Medical Affairs. Dr. Avila previously served as Executive Director, U.S. Medical Strategy and Medical Affairs for COVID-19 at Gilead Sciences.
15 June 2021
Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today positive safety results from Cohort 1 of OASIS, its ongoing Phase 1/2a clinical trial of CLS-AX (axitinib injectable suspension) administered by suprachoroidal injection via Clearside’s SCS Microinjector® in six patients (n=6) with neovascular age-related macular degeneration (wet AMD).
02 June 2021
Bausch Health Companies Inc. (NYSE/TSX: BHC) (“Bausch Health”) and Bausch&Lomb, its leading global eye health business, along with Clearside Biomedical, Inc. (Nasdaq: CLSD) (“Clearside”), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that the U.S. Food and Drug Administration (FDA) has accepted the resubmitted New Drug Application for XIPERE™1 (triamcinolone acetonide suprachoroidal injectable suspension).
binx health Raises $104 Million in Series E Financing
27 May 2021
binx health, a healthcare technology and diagnostics company that makes routine testing convenient by enabling access to care where people live, work, study and shop, today announced the closing of a Series E financing of $104 million.
OCON Healthcare Develops New Women’s Health Devices
24 May 2021
OCON Healthcare, an Israeli FemTech startup, manufactures and commercializes innovative 3D intrauterine devices (IUD) for women who wish to conceive based on its patented IUB (Intra-Uterine Ball) platform.The company has a woman as its chair, Dr. Anula Jayasuriya.
Atea Pharmaceuticals Appoints Jerome Adams, M.D., M.P.H., to Board of Directors
20 May 2021
Atea Pharmaceuticals, Inc., a biopharmaceutical company engaged in the discovery and development of next-generation therapeutics for severe viral infections, today announced the appointment of Jerome Adams, M.D., M.P.H., to its Board of Directors. Dr. Adams most recently served as Surgeon General of the United States and brings a wide range of experience spanning clinical practice, clinical research, public health, and government agency leadership.
18 May 2021
binx health announced the submission of an Emergency Use Authorization (EUA) request to the U.S. Food and Drug Administration (FDA) for the first CLIA-waived CRISPR-based point-of-care (POC) test for COVID-19. binx io is already the first CLIA-waived platform for the molecular detection of chlamydia and gonorrhea in about 30 minutes. binx has now adapted the single-use cartridge for analysis of RNA-based targets, pairing the high performance of Sherlock Biosciences’ proprietary CRISPR technology with binx’s rapid and sensitive proprietary electrochemical detection to create a powerful tool to help combat COVID-19.
Clearside Biomedical Announces First Quarter 2021 Financial Results and Provides Corporate Update
17 May 2021
Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, today reported financial results for first quarter ended March 31, 2021.
Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2021 Financial Results
17 May 2021
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today provided an update on its clinical and regulatory development activities and reported its financial results for the first quarter ended March 31, 2021.
Atea Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update
13 May 2021
Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today reported financial results for the quarter ended March 31, 2021 and provided a corporate update.
14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Big Pharma’s ROI for drug R&D saw 'welcome' rebound in 2023: report
25 April 2024
Orphan drug market to reach $270B by 2028 : Evaluate
25 April 2024
Russian drug for the treatment of viral hepatitis will be exempt from duty in Mongolia
24 April 2024
PM Mishustin: “We need to increase the production of vital and essential drugs in Russia”
24 April 2024